Diabetes Diagnostics Global Market Report 2025

The diabetes diagnostics market size has grown strongly in recent years. It will grow from $25.39 billion in 2024 to $27.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be credited to the rising prevalence of diabetes, an expanding geriatric population, increasing sedentary lifestyles, greater adoption of minimally invasive diagnostics, and the growing prevalence of obesity.

The diabetes diagnostics market size is expected to see strong growth in the next few years. It will grow to $36.72 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be credited to the rising adoption of insulin pumps, advancements in diabetes technology, increasing prevalence of unhealthy lifestyles, a surge in Type 1 and Type 2 diabetes cases, and the expansion of healthcare infrastructure. Key trends include advancements in biosensor technology, innovations in diagnostic technologies, the rise of personalized medicine and targeted therapies, and the development of advanced in vitro diagnostic products.

The increasing prevalence of obesity is expected to drive the growth of the diabetes diagnostics market in the coming years. Obesity is characterized by excessive accumulation of body fat, which raises the risk of several health conditions, including heart disease and diabetes. The growing incidence of obesity is linked to factors such as sedentary lifestyles, higher consumption of processed and high-calorie foods, genetic predisposition, and reduced physical activity. Diabetes diagnostics play a crucial role in obesity management by identifying insulin resistance and glucose metabolism issues early, allowing for timely interventions to prevent weight gain and associated health complications. For example, in September 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2022, 22 states had an adult obesity rate of 35% or higher, up from 19 states in 2021. This increasing obesity rate is contributing to the expansion of the diabetes diagnostics market.

Companies operating in the diabetes diagnostics market are focusing on developing innovative products, such as gestational diabetes diagnostic tools, to broaden their product offerings and meet the rising demand for early detection and management of diabetes during pregnancy. These tools include medical devices and tests designed to detect and monitor gestational diabetes in pregnant women, often involving blood glucose testing, such as the oral glucose tolerance test (OGTT), to evaluate how the body processes sugar during pregnancy. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, introduced the XpressGT RUO kit, a cutting-edge biosensor tool for detecting insulin resistance-related conditions, including gestational diabetes, endometriosis, and liver disease. This kit provides rapid results by measuring 2-hydroxybutyrate (2-HB) levels in venous blood and is compatible with standard clinical analyzers. This innovation is designed to facilitate early diagnostics, potentially improving health outcomes for millions of patients worldwide.

In September 2023, Abbott Laboratories Ltd., a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition aims to strengthen Abbott’s position in diabetes care, expand its FreeStyle Libre portfolio, and advance its efforts in developing connected solutions for more personalized and precise diabetes management. Bigfoot Biomedical Inc. is a US-based medical technology company focused on creating innovative solutions for insulin management.

Major players in the diabetes diagnostics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Novartis AG, 3M Company, Medtronic plc, Regeneron Pharmaceuticals Inc., Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, DexCom Inc, Santen Pharmaceutical Co. Ltd., Topcon Corporation, Tandem Diabetes Care Inc, Ypsomed AG, LifeScan Inc, Nova Biomedical Corporation, Ascensia Diabetes Care Holdings AG, ARKRAY Inc, Optos plc, Bioland Technology Ltd, PTS Diagnostics Inc, AgaMatrix Inc, Senseonics Holdings Inc, and DarioHealth Corp.

North America was the largest region in the diabetes diagnostics market in 2024. The regions covered in diabetes diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetes diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetes diagnostics encompasses the methods and tests used to detect and monitor diabetes by measuring blood glucose levels and other relevant biomarkers. These assessments help identify abnormal glucose metabolism, assess diabetes risk or presence, and support early detection, disease management, and treatment planning.

The primary product types in diabetes diagnostics include blood glucose meters, continuous glucose monitoring devices, lancets, test strips, and others. Blood glucose meters are portable medical devices that measure blood sugar levels by analyzing a small drop of blood, usually from a fingertip, placed on a test strip. These devices are used for Type I diabetes, Type II diabetes, and gestational diabetes across various settings, including hospitals, diagnostic centers, home care, and others.

The diabetes diagnostics market research report is one of a series of new reports that provides diabetes diagnostics market statistics, including the diabetes diagnostics industry global market size, regional shares, competitors with the diabetes diagnostics market share, detailed diabetes diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetes diagnostics industry. This diabetes diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetes diagnostics market consists of revenues earned by entities by providing services such as insulin sensitivity and resistance testing, neuropathy testing services, retinopathy screening services, and diabetes risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes diagnostics market also includes sales of glucose monitoring devices, HbA1c testing kits, and insulin pumps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.